Literature DB >> 21736392

Value-based pricing: incentive for innovation or zero net benefit?

Dyfrig A Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21736392     DOI： 10.2165/11592570-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  15 in total

1.  Pharmacoeconomics: NICE's approach to decision-making.

Authors:  Michael Rawlins; David Barnett; Andrew Stevens
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  Multiple sclerosis risk sharing scheme: a costly failure.

Authors:  James Raftery
Journal:  BMJ       Date:  2010-06-03

3.  Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word.

Authors:  Neil Hawkins; David A Scott
Journal:  Health Econ       Date:  2011-06       Impact factor: 3.046

4.  Value-based pricing of drugs in the UK.

Authors:  David J Webb; Andrew Walker
Journal:  Lancet       Date:  2007-04-28       Impact factor: 79.321

5.  Does health care spending improve health outcomes? Evidence from English programme budgeting data.

Authors:  Stephen Martin; Nigel Rice; Peter C Smith
Journal:  J Health Econ       Date:  2007-12-25       Impact factor: 3.883

6.  NICE and new: appraising innovation.

Authors:  Robin E Ferner; Dyfrig A Hughes; Jeffrey K Aronson
Journal:  BMJ       Date:  2010-01-05

7.  A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.

Authors:  Ulf Persson; Michael Willis; Knut Odegaard
Journal:  Eur J Health Econ       Date:  2009-07-29

Review 8.  The NICE cost-effectiveness threshold: what it is and what that means.

Authors:  Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Patient access schemes for high-cost cancer medicines.

Authors:  Steve Williamson
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

10.  Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Authors:  Adrian Towse
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335
View more
  14 in total

1.  Defining rewardable innovation in drug therapy.

Authors:  Jeffrey K Aronson; Robin E Ferner; Dyfrig A Hughes
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

2.  The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?

Authors:  James F O'Mahony; Diarmuid Coughlan
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

Review 3.  Market access of cancer drugs in European countries: improving resource allocation.

Authors:  Kim Pauwels; Isabelle Huys; Minne Casteels; Katelijne De Nys; Steven Simoens
Journal:  Target Oncol       Date:  2013-11-19       Impact factor: 4.493

4.  Operationalizing value-based pricing of medicines : a taxonomy of approaches.

Authors:  Jon Sussex; Adrian Towse; Nancy Devlin
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

Review 5.  The Value of Medicines: A Crucial but Vague Concept.

Authors:  Fernando Antoñanzas; Robert Terkola; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

6.  Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.

Authors:  Di Sun; Jennifer R Heimall; Matthew J Greenhawt; Nancy J Bunin; Marcus S Shaker; Neil Romberg
Journal:  JAMA Pediatr       Date:  2022-02-01       Impact factor: 16.193

7.  Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.

Authors:  Warren G Linley; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

8.  Pharmacoeconomics.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

9.  Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.

Authors:  Joshua Pink; Steven Lane; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

10.  Stakeholder opinions on value in healthcare.

Authors:  Robert Terkola; Fernando Antoñanzas; Maarten Postma
Journal:  Eur J Hosp Pharm       Date:  2017-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.